Project achieves 30% reduction in hospital acquired infections and 24% reduction in the incidence of multi-drug resistant organisms
The acquisition will build on AstraZeneca’s expertise in respiratory syncytial virus
he lower sales in the current quarter are mainly on account of a one?time impact on the company’s India business
MASH is a chronic and progressive liver disease characterised by fat accumulation and inflammation in the liver,
These re-agent and diagnostic test kits come with 99.7% accuracy
Zydus’s revenue growth was led by India and EU formulations businesses in addition to that in the emerging markets.
Ayush is expanding beyond wellness to therapeutic wellness
The company recently received CEP certificate approval for Losartan Potassium by EDQM
Indian Pharma Post brings together the views of industry leaders on the Interim Union Budget 2024-25 announcement and its impact on the industry
Revenue from Operations stood at Rs. 2,607 crore, 25% YoY growth. Domestic revenue at Rs. 2,400 crore, 20% YoY growth and export revenue at Rs. 207 crore, 118% YoY growth
Subscribe To Our Newsletter & Stay Updated
